Kymera Therapeutics, Inc. (KYMR)
NASDAQ: KYMR · Real-Time Price · USD
90.43
+0.53 (0.59%)
At close: Jun 18, 2026, 4:00 PM EDT
89.30
-1.13 (-1.25%)
After-hours: Jun 18, 2026, 4:54 PM EDT
Kymera Therapeutics Employees
Kymera Therapeutics had 253 employees as of March 31, 2026. The number of employees increased by 45 or 21.63% compared to the same quarter last year.
Employees
253
Change
45
Growth
21.63%
Revenue / Employee
$203,462
Profits / Employee
-$1,245,075
Market Cap
7.44B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 253 | 45 | 21.63% |
| Dec 31, 2025 | 238 | 50 | 26.60% |
| Sep 30, 2025 | 225 | 41 | 22.28% |
| Jun 30, 2025 | 218 | 37 | 20.44% |
| Mar 31, 2025 | 208 | 22 | 11.83% |
| Dec 31, 2024 | 188 | 1 | 0.53% |
| Sep 30, 2024 | 184 | -8 | -4.17% |
| Jun 30, 2024 | 181 | 0 | - |
| Mar 31, 2024 | 186 | 12 | 6.90% |
| Dec 31, 2023 | 187 | 20 | 11.98% |
| Sep 30, 2023 | 192 | 23 | 13.61% |
| Jun 30, 2023 | 181 | 21 | 13.13% |
| Mar 31, 2023 | 174 | 31 | 21.68% |
| Dec 31, 2022 | 167 | 26 | 18.44% |
| Sep 30, 2022 | 169 | 33 | 24.26% |
| Jun 30, 2022 | 160 | 48 | 42.86% |
| Mar 31, 2022 | 143 | 51 | 55.43% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| ImmunityBio | 691 |
| Vaxcyte | 507 |
| Halozyme Therapeutics | 423 |
| Rhythm Pharmaceuticals | 414 |
| TG Therapeutics | 399 |
| Immunovant | 315 |
| Apogee Therapeutics | 261 |
| Praxis Precision Medicines | 168 |
KYMR News
- 3 days ago - Kymera Therapeutics participates in a conference call with JPMorgan - TheFly
- 9 days ago - Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting - GlobeNewsWire
- 10 days ago - Healthcare ETFs: From Broad Exposure to Big Breakthroughs - ETF Trends
- 12 days ago - Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration - GlobeNewsWire
- 12 days ago - Kymera Therapeutics Slides: Corporate presentation - Filings
- 12 days ago - Kymera Therapeutics Appoints Penny Carlson as Senior Vice President, Development Operations - GlobeNewsWire
- 13 days ago - Kymera Therapeutics presents preclinical lupus data for KT-579 - TheFly
- 13 days ago - Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses - GlobeNewsWire